We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Measuring Hope and Hopelessness in Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00581880
First Posted: December 28, 2007
Last Update Posted: January 15, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Fordham University
Calvary Hospital, Bronx, NY
Peter MacCallum Cancer Centre, Australia
Information provided by:
Memorial Sloan Kettering Cancer Center
  Purpose
The purpose of this study is to develop an accurate and useful way of measuring patients' thoughts and feelings about hope and hopelessness as they relate to their illness. Doctors and psychologists from Memorial Sloan-Kettering Cancer Center, Calvary Hospital, the Peter MacCallum Cancer Centre, and Fordham University are working together to design a new measure. Findings from this research will help us study the nature of illness and develop improved methods of diagnosis and treatment. We hope what we learn from you will help us learn more about how to care better for patients with cancer and other severe illnesses.

Condition Intervention
Advanced Cancer Behavioral: questionnaires

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Measuring Hope and Hopelessness in Cancer

Further study details as provided by Memorial Sloan Kettering Cancer Center:

Primary Outcome Measures:
  • To explore and better understand the construct of hopelessness as it applies to terminally ill cancer patients. [ Time Frame: conclusion of study ]
  • To develop a brief self-report measure of hopelessness grounded in the construct of hopelessness as it applies to terminally ill cancer patients. [ Time Frame: conclusion of study ]

Secondary Outcome Measures:
  • To establish the reliability and validity of this newly developed measure of hopelessness in a large sample of terminally ill cancer patients. [ Time Frame: conclusion of study ]

Enrollment: 288
Study Start Date: January 2005
Study Completion Date: January 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1
Terminally Ill patients
Behavioral: questionnaires
A battery of questionnaires concerning your thoughts, opinions, and attitudes about your illness and outlook on life. In addition, we will ask to provide some background information about you and your illness. The questions will take approximately 30 to 45 minutes to complete. You fill out the questionnaire once only.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects will be recruited in equal numbers from Memorial Hospital and Calvary Hospital or Peter MacCallum Cancer Centre at each stage of data collection.
Criteria

Inclusion Criteria:

  • 18 years of age or older.
  • Patients who are able to understand verbal and written English.
  • Diagnosis of cancer.
  • Patients with advanced cancer receiving ambulatory or inpatient care at Memorial Sloan-Kettering Cancer Center in New York City. Patients at Calvary Hospital and Peter MacCallum Cancer Centre admitted for palliative care will also be eligible for participation in this study

Exclusion Criteria:

  • The presence of a psychotic mental disorder (e.g., Bipolar Disorder, Schizophrenia, Schizo-affective illness, psychosis due to substance abuse) as indicated in medical chart.
  • Cognitive impairment so severe (i.e., Mini-Mental State exam score of less than 20) that, in the opinion of the Principal Investigator or Project Coordinator, would interfere with a patient's ability to give informed consent for research.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00581880


Locations
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Fordham University
Calvary Hospital, Bronx, NY
Peter MacCallum Cancer Centre, Australia
Investigators
Principal Investigator: William Breitbart, MD Memorial Sloan Kettering Cancer Center
  More Information

Additional Information:
Responsible Party: William Breitbart, MD, Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00581880     History of Changes
Other Study ID Numbers: 04-145
First Submitted: December 21, 2007
First Posted: December 28, 2007
Last Update Posted: January 15, 2009
Last Verified: January 2009

Keywords provided by Memorial Sloan Kettering Cancer Center:
end stage
Terminally Ill